Related Experiment Video
Updated: Feb 15, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Modified 3-week schedule of gemcitabine plus cisplatin for non-small cell lung cancer treatment
Antonello Veccia1, Viviana Murgia, Mariachiara Dipasquale
1Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d'Oro, Trento, Italy.
Purpose:
Gemcitabine-cisplatin combination is one of the most used schedules for non small cell lung cancer (NSCLC). Aiming to enhance dose intensity and reduce toxicity, the original 4-week schedule was modified or transformed into a 3-week schedule. The purpose of this study was to report the efficacy and tolerability of a modified 3-week regimen of gemcitabine-cisplatin.
Methods:
Our patients were treated with gemcitabine (1000 mg7sol;m2) on days 1, 8 and cisplatin on day 8 (75-100 mg/m2). The toxicity was recorded according to the NCIC criteria.
Results:
From October 2000 to December 2009 a consecutive series of 196 patients with a median age of 62 years and III-IV stage NSCLC received gemcitabine-cisplatin as induction therapy (76 patients) or palliative treatment (120 patients). The median dose intensity was 89%. In relation to day 8 of chemotherapy, 16.2% of the treatments were delayed due to hematologic toxicities. Grade 3-4 anaemia, neutropenia and thrombocytopenia was reported in 3.5, 43.8 and 4.6%, respectively. Response rate (RR) and median overall survival (OS) were 74% and 11 months in patients with locally advanced disease, and 46.7% and 9 months in metastatic patients, respectively.
Conclusions:
In comparison with standard or modified schedules of literature, our modified 3-week regimen of gemcitabine- cisplatin demonstrated to be equally active, similar for dose intensity and well tolerated, with better hematologic toxicity profile in terms of anaemia and thrombocytopenia.
Related Concept Videos
Reinforcement Schedules
Once a behavior is learned,...
Treatment Resistant Cancers
Lung Capacity
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3
Modified Boxplots
However, the box plot does not tell the reader about outliers - values that lie far from the center of the data. We can modify the standard box and whisker plot to identify the outliers and visualize the actual spread of the data in a sample.
Initially, we calculate the adjusted...
Cancer Cell Migration through Invadopodia

